Ajax Therapeutics has received FDA approval for its investigational new drug application for AJ1-11095, a novel Type II JAK2 inhibitor, intended for the management of myelofibrosis.

FDA grants priority review to Dupixent® (dupilumab) sBLA for treating teens with chronic rhinosinusitis and nasal polyps.

Cardurion Pharmaceuticals Reports Encouraging Outcomes from Phase 2a CARDINAL-HF Study of PDE9 Inhibitor in Heart Failure Patients.

Anaptys released encouraging initial outcomes from the GEMINI-2 Phase 3 study of Imsidolimab (IL-36R) for treating Generalized Pustular Psoriasis.

First Wave will concentrate on advancing a portfolio of gastrointestinal disease therapies, including latiglutenase, which encompasses multiples late-stage clinical assets.

Fusion Pharmaceuticals revealed that the initial participant has received a dose in the AlphaBreak Trial's Phase 2 study of FPI-2265 for treating metastatic castration-resistant prostate cancer.

Celltrion USA now offers a budget-friendly adalimumab-aaty biosimilar as an alternative to HUMIRA® at reduced wholesale prices.

X4 Pharmaceuticals is a biotech company specialized in the development of therapeutic drugs focusing on CXCR4 and immunological biology.

WestGene proudly declares a significant breakthrough as the FDA grants IND approval for its mRNA-based cancer vaccine, WGc-043.

PeptiDream is a biotechnology company based in Japan, focused on the development of innovative macrocyclic peptide drugs.

Revance Therapeutics, Inc. has initiated the market release of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, aimed at treating cervical dystonia.

Shionogi & Co., Ltd. along with Maze Therapeutics, Inc. have declared a global exclusive licensing deal for MZE001, an innovative therapy aimed at addressing Pompe Disease.